Please login to the form below

Not currently logged in
Email:
Password:

cost-effectiveness

This page shows the latest cost-effectiveness news and features for those working in and with pharma, biotech and healthcare.

Roche’s Hemlibra scores broader NHS funding

Roche’s Hemlibra scores broader NHS funding

NHS England will have undoubtedly driven a hard bargain during confidential talks on the drug's price in exchange for market access, though it releases scant details about its cost effectiveness

Latest news

More from news
Approximately 3 fully matching, plus 545 partially matching documents found.

Latest Intelligence

  • It’s not the end of the world, is it? It’s not the end of the world, is it?

    not claim to offer value, cost-effectiveness or some other paraphrasing of the value-based mantra. ... our industry (and indeed, any industry) offers is not the best possible value for money when considered from a strictly full-cost for full-benefit

  • The UK’s new medicines pricing deal – opportunities and risks for pharma The UK’s new medicines pricing deal – opportunities and risks for pharma

    This includes briefing committees on the types of uncertainty and those that have the most significant impact on cost-effectiveness. ... This is further evidence of the influence of NHSE. New incentives to greater cost-effectiveness.

  • The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt

    And, to me, there are three. The first is that the government has threatened the industry during every recent PPRS negotiation with a reduction in the standard NICE cost-effectiveness threshold. ... the government dictates, or forcing all companies into

  • The Orkambi blame game The Orkambi blame game

    on the cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... cost-effectiveness – something which NICE is unable to do.

  • #OrkambiNow? #OrkambiNow?

    the UK, and has reflected badly on the pharma company, budget holder NHS England and cost effectiveness watchdog NICE. ... per patient per year price – comparable to the cost of older and less effective CF medicines such as Pulmozyme.

More from intelligence
Approximately 0 fully matching, plus 59 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics